Related Experiment Video

Updated: Feb 15, 2026

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

6.1K

Patient-derived tumor organoids for new drug development: promises and challenges

Meijun He1, Ying Wu1, Furong Du2

  • 1Department of Obstetrics and Gynecology, The 920th Hospital of Joint Logistics Support Force, Kunming 650032, Yunnan, China.

Investigational New Drugs
|February 14, 2026
PubMed

Insights

Patient-derived tumor organoids (PDTOs) offer a promising preclinical model for cancer research. These organoids accurately mimic patient tumors, accelerating new drug development and overcoming traditional research challenges.

Area of Science:

  • Oncology
  • Biotechnology
  • Drug Discovery

Background:

  • Antitumor drug development faces challenges like long R&D cycles and variable efficacy.
  • Patient-derived tumor organoids (PDTOs) are emerging as a novel preclinical cancer model.
  • PDTOs are 3D stem cell-derived microstructures that mimic original tumor tissues.

Purpose of the Study:

  • To review the types of organoids available for cancer research.
  • To explore the application of PDTOs in new drug development.
  • To discuss the challenges and opportunities associated with PDTOs in drug discovery.

Main Methods:

  • Review of existing literature on organoid technology and PDTO applications.
  • Analysis of PDTO capabilities in recapitulating tumor biology and heterogeneity.
  • Evaluation of PDTOs in preclinical drug screening and development.

Main Results:

  • PDTOs faithfully recapitulate biological and molecular features of original tumors.
  • PDTOs preserve tumor heterogeneity, offering a more accurate model.
  • PDTOs demonstrate significant potential for efficient drug screening.

Conclusions:

  • PDTOs represent a powerful tool to overcome limitations in antitumor drug development.
  • Further research into PDTOs can provide valuable insights for accelerating new drug discovery.
  • Addressing challenges will enhance the utility of PDTOs in personalized cancer medicine.
Keywords:
Diagnostic markersDrug developmentNovel drug targetsStem cellsTumor organoids

More Related Videos

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

2.4K
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.3K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
280
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
251
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
717